**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was done. Co-authors will be added in a separate section.**
Lisa Mendelson, Boston University Avedisian and Chobanian School of Medicine, Boston, Massachusetts

**Main Body of the Abstract**
In order to characterize the spectrum of amyloidosis types, clinical presentations and treatments in genitourinary (GU) tract amyloidosis, we reviewed our center’s experience spanning 30 years and 101 biopsy-proven cases.  Amyloid typing was performed on available tissue samples. Localized light chain (ALoc) amyloidosis was defined as amyloid deposition limited to one site without signs of amyloid-related systemic disease or markers of plasma cell dyscrasia. Cases of amyloid derived from hepatic proteins—e.g., transthyretin (TTR), serum amyloid A (SAA), apolipoprotein A1 (AApoA1) — were designated as systemic disease, as were cases fulfilling the diagnostic criteria for systemic light chain (AL) amyloidosis.
Of 101 patients with GU amyloidosis, 53% (n=54) had ALoc amyloidosis; 19% (n=19) had systemic AL amyloidosis; 25% (n=25) had transthyretin amyloidosis; 4% (n=2) had serum AA amyloidosis; and 1 had AApoA1 amyloidosis. Hematuria was the presenting feature in 99% of lower GU tract (bladder) cases, whereas flank pain was most common (55%) in cases of upper GU tract amyloidosis.
Seven patients with ALoc amyloidosis underwent low-dose (20Gy) external beam radiotherapy (EBRT). Of the three bladder patients who underwent EBRT none required surgical intervention after EBRT. In the four patients with ureter involvement there was one intervention after EBRT, palliative nephrectomy for ongoing pain due to chronic hydronephrosis. Compared to ALoc amyloidosis, patients with systemic disease (ATTR, AL or AA amyloidosis) underwent surgical resections less frequently (6% versus 56%) as management efforts were focused on decreasing the production of and/or stabilizing the amyloidogenic precursor proteins.



Clinical presentation and treatment of genitourinary amyloidosis: A single referral center 30-year experience PC148 (#371)

We invite you to attend the XIX International Symposium on Amyloidosis to be held in Rochester, MN.

This symposium is organized as a hybrid meeting (with the focus on in-person) held from Sunday, May 26 through Thursday, May 30, 2024.

Together with the ISA Board and members of Mayo Clinic, a very attractive scientific hybrid program is being planned. The program will cover a variety of types of systemic amyloidosis: ATTR (hereditary and wild-type), AL (light-chain), AA and less frequent forms. There will be key lectures, specific symposia including those company sponsored, oral presentations and poster sessions of accepted abstracts.

COURSE DESCRIPTION
This program will provide a comprehensive review of state-of-the-art education in systemic amyloidosis: basic science, pathophysiology, diagnosis, current and emerging treatments. Scientific presentations will include competitive oral and poster abstracts. The rapid evolution of scientific discovery and expanding treatment options has created tremendous interest in the field and this meeting will fill and important gap in educating scientists and clinicians.